Ocugen

October 31 began the five day celebration of Diwali, also known as "The Festival of Lights." Diwali symbolizes the spiritual victory of light over darkness, good over evil, and knowledge over ignorance. Happy Diwali to all who celebrate!

The Ocugen team gathered for a bake off to celebrate a very spooky Halloween. It was a fun way to recharge and recognize the group’s talents outside of the office! #TeamOcugen #HappyHalloween

We're #hiring a new AD/Manager, Regulatory Affairs in Malvern, Pennsylvania. Apply today or share this post with your network.

We're #hiring a new Manager, Regulatory Affairs in Malvern, Pennsylvania. Apply today or share this post with your network.

We're #hiring a new Senior Director Regulatory Affairs in Malvern, Pennsylvania. Apply today or share this post with your network.

Today, Ocugen announced that it will host a Clinical Showcase focusing on encouraging updates from Ocugen’s ongoing gene therapy trials and featuring patients, investigators and thought leaders. For more information, please read the full press release: https://lnkd.in/edA8Yp8j

Thank you CGTLive for highlighting Ocugen's latest clinical milestone and continuously recognizing the modifier gene therapy platform as a novel approach to reset the functional network of the retina. #GeneTherapy #IRD #ClinicalTrials

Today Ocugen announced that the Data and Safety Monitoring Board (DSMB) for the OCU410ST GARDian clinical trial recently convened and approved enrollment for the second phase of the Phase 1/2 clinical trial. Read the full press release here: https://bit.ly/48ex8Mh

Ocugen is wrapping up a successful AAO 2024 meeting!   Highlights include:   Meeting with key opinion leaders and advocates at Booth #5156 and sharing more about the science behind our modifier gene therapy platform and the progress of our three clinical stage programs   Hosting a great AAO investigator meeting for OCU400, OCU410 GA and ST. Special thanks to Lejla Vajzovic, MD, FASRS and Benjamin Bakall, MD, PhD for presenting at the session and all investigators for their support   The OCU400 Phase 1/2 data presented during the poster presentation by Dr. Byron L. Lam, Bascom Palmer Eye Institute, University of Miami School of Medicine, with key takeaways: ·OCU400 therapy showed safety and efficacy in RP and LCA, with 90% of RP patients achieving BCVA stabilization or improvement ·The gene-agnostic approach of OCU400 targets the NHR gene NR2E3, addressing multiple genetic mutations linked to RP and LCA Read more here: https://bit.ly/48i7oPd   Always great to reconnect and make new connections with industry leaders at this important meeting. #AAO2024 #GeneTherapy #IRD #GA

Ocugen Chairman, Chief Executive Officer, and Co-founder, Dr. Shankar Musunuri, was recently featured on the Smart Money Circle Show with Adam Sarhan. Dr. Musunuri provides more on the competitive advantages of modifier gene therapy, Ocugen's approach to managing risk, and the Company's plans for future growth. He also shares timeless advice and lessons learned in his own career. Thanks Adam for providing Ocugen visibility among a new audience of individual investors. #IR #CourageousInnovation #Grit https://lnkd.in/d4t8ff4T